To Screen or Not to Screen? Examining the Arguments Against Screening for Atrial Fibrillation

Heart Lung and Circulation

Volumn 26, Issue 9, 2017, Pages 880-886

  Neubeck, Lis ^a,b,c   Orchard, Jessica ^b   Lowres, Nicole ^b   Freedman, S Ben ^b,d  

^a EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d University of Sydney   (Australia)

Author keywords

Atrial fibrillation; Screening; Technology

Indexed keywords

ANTICOAGULANT AGENT;

ASYMPTOMATIC DISEASE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; EARLY DIAGNOSIS; FINANCIAL MANAGEMENT; HEALTH PROGRAM; HUMAN; LOW RISK PATIENT; MEDICAL TECHNOLOGY; PAROXYSMAL ATRIAL FIBRILLATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK MANAGEMENT; RISK REDUCTION; TREATMENT RESPONSE; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; ELECTROCARDIOGRAPHY; GLOBAL HEALTH; MASS SCREENING; MORBIDITY; RISK FACTOR; TRENDS;

ATRIAL FIBRILLATION; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; GLOBAL HEALTH; HUMANS; MASS SCREENING; MORBIDITY; RISK FACTORS;

EID: 85020675360     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2017.05.118     Document Type: Review

References (46)

1. Chugh, S.S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benkamin, E.J., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:80 (2014), 837–847.
2. Lloyd-Jones, D.T., Wang, E., Leip, M., Larson, D., Levy, R., Vasan, R., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:9 (2004), 1042–1046.
3. Boriani, G., Laroche, C., Diemberger, I., Fantecchi, E., Popescu, M.I., Rasmussen, L.H., et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. The American Journal of Medicine 128:5 (2015), 509–518 e502.
4. Leyden, J.M., Kleinig, T.J., Newbury, J., Castle, S., Cranefield, J., Anderson, C.S., et al. Adelaide Stroke Incidence Study Declining Stroke Rates but Many Preventable Cardioembolic Strokes. Stroke 44:5 (2013), 1226–1231.
5. Freedman, B., Potpara, T.S., Lip, G.Y., Stroke prevention in atrial fibrillation. Lancet 388 (2016), 806–817.
6. Gladstone, D.J., Spring, M., Dorian, P., Panzov, V., Thorpe, K.E., Hall, J., et al. Atrial fibrillation in patients with cryptogenic stroke. New England Journal of Medicine 370:26 (2014), 2467–2477.
7. Gladstone, D.J., Bui, E., Fang, J., Laupacis, A., Lindsay, M.P., Tu, J.V., et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:1 (2009), 235–240.
8. Saposnik, G., Gladstone, D.J., Raptis, R., Zhou, L., Hart, R.G., Atrial Fibrillation in Ischemic Stroke. Stroke 44:1 (2013), 99–104.
9. National Institute of Clinical Excellence, Atrial fibrillation: the management of atrial fibrillation. 2014.
10. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 146:12 (2007), 857–867.
11. Heijnsdijk, E.A., Wever, E.M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., et al. Quality-of-life effects of prostate-specific antigen screening. New England Journal of Medicine 367:7 (2012), 595–605.
12. Wilson, J., Jungner, G., Principles and Practice of Screening for Disease World Health Organization Public Health Papers. 1968 No. http://apps.who.int/iris/handle/10665/37650 (Accessed 30 January 2017).
13. United Kingdom National Screening Committee. The UK NSC recommendation on Atrial Fibrillation screening in adults. Available at: https://legacyscreening.phe.org.uk/atrialfibrillation. Accessed 27/01/207. 2014.
14. Martinez, C., Katholing, A., Freedman, S.B., Adverse prognosis of incidentally detected ambulatory atrial fibrillation. Thromb Haemost 112:2 (2014), 276–286.
15. Hohnloser, S.H., Vamos, M., Not All Types of Atrial Fibrillation Carry the Same Stroke Risk, but Most Benefit From Oral Anticoagulation. Circ Arrhythm Electrophysiol, 10(1), 2017.
16. Healey, J.S., Connolly, S.J., Gold, M.R., Israel, C.W., Van Gelder, I.C., Capucci, A., Subclinical atrial fibrillation and the risk of stroke. New England Journal of Medicine 366:2 (2012), 120–129.
17. Hess, P.L., Healey, J.S., Granger, C.B., Connolly, S.J., Ziegler, P.D., Alexander, J.H., et al. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. JAMA Cardiol 2:3 (2017), 324–331.
18. Van Gelder, I., Healey, J., Crijns, H., Wang, J., Hohnloser, S.H., Gold, M.R., et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in assert. Eur Heart J(Mar), 2017, 10.1093/eurheartj/ehx042.
19. Potter, B.J., Le Lorier, J., Taking the pulse of atrial fibrillation. Lancet 386 (2015), 113–115.
20. Deveugele, M., Derese, A., van den Brink-Muinen, A., Bensing, J., De Maeseneer, J., Consultation length in general practice: cross sectional study in six European countries. BMJ, 325(7362), 2002, 472.
21. Sneed, N., Hollerbach, A., Accuracy of heart rate assessment in atrial fibrillation. Heart & Lung: the Journal of Critical Care 21:5 (1991), 427–433.
22. Taggar, J.S., Coleman, T., Lewis, S., Heneghan, C., Jones, M., Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. European Journal of Preventive Cardiology 23:12 (2016), 1330–1338.
23. Orchard, J., Freedman, S.B., Lowres, N., Peiris, D., Neubeck, L., iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Australian Family Physician, 43(5), 2014, 315.
24. MacHaalany, J.Y., Yam, J., Ruddy, T.D., Abraham, A., Chen, L., Beanlands, R.S., et al. Potential clinical and economic consequences of noncardiac incidental findings on cardiac computed tomography. Journal of the American College of Cardiology 54:16 (2009), 1533–1541.
25. Chan, P.H., Wong, C.K., Poh, Y.C., Pun, L., Leung, W.W.C., Wong, Y.F., et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. Journal of the American Heart Association, 5(7), 2016, e003428.
26. Tieleman, R., Plantinga, Y., Rinkes, D., Bartels, G.L., Posma, J.L., Cator, R., et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 16:9 (2014), 1291–1295.
27. Lau, J., Lowres, N., Neubeck, L., Brieger, D., Sy, R., Galloway, C., et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int. J. Cardiol. 165 (2013), 193–194.
28. Lloyd-Jones, D., Wang, T., Leip, E., Larson, M., Levy, D., Vasan, R., et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 10:3 (2013), 315–319.
29. Marazzi, G., Iellamo, F., Volterrani, M., Lombardo, M., Pelliccia, F., Righi, D., et al. Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients. Advances in Therapy 29:1 (2012), 64–70.
30. Kearley, K., Selwood, M., Van den Bruel, A., Thompson, M., Mant, D., Hobbs, F.R., et al. Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open, 4(5), 2014, e004565.
31. Wiesel, J., Arbesfeld, B., Schechter, D., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. The American Journal of Cardiology 114:7 (2014), 1046–1048.
32. Freedman, S.B., Camm, J., Calkins, H., Healey, J., Rosenqvist, M., Wang, J., et al. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation 135:19 (2017), 1851–1867.
33. Neubeck, L., Lowres, N., Benjamin, E.J., Freedman, S.B., Coorey, G., Redfern, J., The mobile revolution[mdash]using smartphone apps to prevent cardiovascular disease. Nat Rev Cardiol 12:6 (2015), 350–360.
34. Health Information and Quality Authority. Health technology assessment (HTA) of a national screening programme for atrial fibrillation in primary care, 2015. Accessed 20th February 2017.
35. Maeda, K., Shimbo, T., Fukui, T., Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. Journal of Medical Screening 11:2 (2004), 97–102.
36. Hobbs, F.R., Fitzmaurice, D., Mant, J., Murray, E., Jowett, S., Bryan, S., et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technology Assessment, 9(40), 2005 93pp.
37. Aronsson, M., Svennberg, E., Rosenqvist, M., Engdahl, J., Al-Khalili, F., Friberg, L., et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 17:7 (2015), 1023–1029.
38. Lowres, N., Krass, I., Neubeck, L., Redfern, J., McLachlan, A.J., Bennett, A.A., et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 111:6 (2014), 1167–1176.
39. Rhys, G., Azhar, M., Foster, A., Screening for atrial fibrillation in patients aged 65 years or over attending annual flu vaccination clinics at a single general practice. Qual Prim Care 21:2 (2013), 131–140.
40. Smyth, B.P., Marsden, P., Corcoran, R., Walsh, R., Brennan, C., McSharry, K., Opportunistic screening for atrial fibrillation in a rural area. QJM 109:8 (2016), 539–543.
41. Jacobs, M.S., Kaasenbrood, F., Postma, M.J., Van Hulst, M., Tieleman, R.G., Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace, 2016 pii: euw285.
42. Lowres, N., Neubeck, L., Salkeld, G., Krass, I., McLachlan, A.J., Redfern, J., Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. International Journal of Clinical Pharmacy 37:6 (2015), 1111–1120.
43. Pricewaterhouse Coopers, The economic costs of Atrial Fibrillation in Australia. National Stroke Foundation, June 2010.
44. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 37:38 (2016), 2893–2962.
45. Lowres, N., Neubeck, L., Redfern, J., Freedman, S., Community Screening Programs to Identify Unknown Atrial Fibrillation: A Systematic Review. Heart, Lung and Circulation, 21(Supplement 1), 2012, S4.
46. Friberg, L., Engdahl, J., Frykman, V., Svennberg, E., Levin, L.-Å., Rosenqvist, M., Population screening of 75-and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 15:1 (2013), 135–140.